Investigational new drugs for the treatment of resistant pneumococcal infections

被引：27

作者：

Hoffman-Roberts, HL ^{[1
]}

Babcock, EC ^{[1
]}

Mitropoulos, IF ^{[1
]}

机构：

[1] Coll Pharm, Oklahoma City, OK 73190 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 08期

关键词：

ceftobiprole; dalbavancin; faropenem; garenoxacin; investigational antibiotics; oritavancin; pneumonia; resistance; RWJ-442831; sitafloxacin; Streptococcus pneumoniae;

D O I：

10.1517/13543784.14.8.973

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Antibiotic resistance in Streptococcus pneumoniae is not only increasing with penicillin but also with other antimicrobial classes including the macrolides, tetracyclines and sulfonamides. This trend with antibiotic resistance has highlighted the need for the further development of new anti-infectives for the treatment of pneumococcal infections, particularly against multi-drug resistant pneumococci. Several new drugs with anti-pneumococcal activity are at various stages of development and will be discussed in this review. Two new cephalosporins with activity against S. pneumoniae include ceftobiprole and RWJ-54428. Faropenem is in a new class of beta-lactam antibiotics called the penems. Structurally, the penems are a hybrid between the penicillins and cephalosporins. Sitafloxacin and garenoxacin are two new quinolones that are likely to have a role in treating pneumococcal infections. Oritavancin and dalbavancin are glycopeptides with activity against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus spp. as well as multi-drug resistant pneumococci. Tigecycline is the first drug in a new class of anti-infectives called the glycycyclines that has activity against penicillin-resistant pneumococci.

引用

页码：973 / 995

页数：23

共 120 条

[1] Characterization of the penetration of garenoxacin into the breast milk of lactating women [J].